Poland· PL-100110895
Carzap
A candesartan product containing candesartanum cilexetili, registered in Poland by Zentiva, k.s.. The same ATC class is registered in 16 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Candesartan is registered in 16 of 19 countries.
Countries holding a registration under ATC C09CA06 (candesartan), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Candesartan · ATC C09CA06
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of candesartan costs, country by country.
Normalised to the WHO defined daily dose (8 mg), the median price runs from $0.15 in Italy to $0.36 in Switzerland — a ×2.3 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Candesartan · price per daily dose (8 mg)
USD · FX 28 Sept 2026
- CH Switzerland$0.36
- ES Spain$0.21
- IT Italy$0.15
The record
At a glance
URPL (Poland)- Active substance
- Candesartanum cilexetili
- Manufacturer
- Zentiva, k.s.
- Country
- Poland (PL)
- ATC code
- C09CA06
- ATC class
- Candesartan
- Defined daily dose
- 8 mg, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 8
1 priced- gtin0590999093726428 szt.PLN 49.47
- gtin05909990937240
- gtin05909990937257
- gtin05909990937271
- gtin05909990937288
- gtin05909990937295
- gtin05909990937301
- gtin05909990937332
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
81 interactions on record for candesartan.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Candesartan · interactions on record
81 records
81 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame class
Other records under C09CA06
Candesartan, as other registers publish it.
- CanadaACH-CANDESARTANACCORD HEALTHCARE INC
- CanadaACH-CANDESARTANACCORD HEALTHCARE INC
- CanadaACH-CANDESARTANACCORD HEALTHCARE INC
- CanadaAG-CANDESARTAN TABLETSANGITA PHARMA INC.
- CanadaAG-CANDESARTAN TABLETSANGITA PHARMA INC.
- CanadaAG-CANDESARTAN TABLETSANGITA PHARMA INC.
- FinlandAmiasOrifarm Oy
- FinlandAmiasOrifarm Oy
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c603122c-59d0-4d23-85ac-ea3fc7f72e65 GET /v1/drugs/c603122c-59d0-4d23-85ac-ea3fc7f72e65?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki",
"source": "urpl",
"strength": "32 mg",
"packaging": "05909990937240 ¦ Rp ¦ 72731\n7 tabl.\n05909990937257 ¦ Rp ¦ 72732\n14 tabl.\n05909990937264 ¦ Rp ¦ 72733\n28 tabl.\n05909990937271 ¦ Rp ¦ 72734\n30 tabl.\n05909990937288 ¦ Rp ¦ 72735\n56 tabl.\n05909990937295 ¦ Rp ¦ 72736\n70 tabl.\n05909990937301 ¦ Rp ¦ 72737\n90 tabl.\n05909990937332 ¦ Rp ¦ 72738\n98 tabl.",
"substance": "Candesartanum cilexetili 32 mg",
"common_name": "Candesartanum cilexetili",
"pl_product_id": "100110895",
"pozwolenie_nr": "19638",
"auth_procedure": "DCP",
"authorisation_validity": "Bezterminowe"
}See everything about candesartan.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.